| prof - Donnerstag, 15. Juni 2006 - 12:14 |
| Kauf 2400 Stück zum nächsten Frankfurter Kurs - Prof (Es handelt sich um eine "konservative" Silbermine) |
| chinaman - Donnerstag, 15. Juni 2006 - 17:48 |
| Aber nicht um einen charttechnischen Kauf ;-))) Gruß Chinaman |
| prof - Freitag, 16. Juni 2006 - 14:32 |
| @chinaman: erwischt - Prof |
| chinaman - Freitag, 4. August 2006 - 19:24 |
| Was noch kein Chartkauf war, kann ja noch ein Chartkauf werden ... COEUR D ALENE startet wieder... http://www.godmode-trader.de/news/?ida=477232&idc=8 Gruß Chinaman |
| chinaman - Sonntag, 27. August 2006 - 09:14 |
| 25.08.2006 16:10 Coeur d'Alene Mines work halted by court COEUR D'ALENE, Idaho (AFX) - Coeur d'Alene Mines (Nachrichten) Corp., a silver and gold miner, on Friday said work in one part of its Kensington Gold mine near Juneau Alaska has been temporarily halted by the U.S. Ninth Circuit Court of Appeals in San Francisco. The injunction against construction activities in the mine's tailing facility, an operation that process waste from mining activities, was sought by the Southeast Alaska Conservation Council and the Sierra Club. The environmental groups are appealing an Alaska Federal District Court decision from earlier this month that upheld a U.S. Army Corps of Engineers permit issued to the tailings facility. The two groups claimed the permit is not valid. Coeur d'Alene Mines is spending about $100 million to build the mine. Shares of Coeur d'Alene Mines fell 1 cent to $5.35 on the New York Stock Exchange. Copyright 2006 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. |
| prof - Dienstag, 12. September 2006 - 12:31 |
| Das erst am WE erhöhte SL ist gestern gefallen. Bei dem volatilen Ag-Markt bin ich aber großzügig/inkonsequent und halte weiter! Prof |
| chinaman - Dienstag, 12. September 2006 - 12:36 |
| "Bei dem volatilen Ag-Markt bin ich aber großzügig/inkonsequent und halte weiter! " Hätte ich auch so gemacht ... Aber Du als Chartie ??? Mache mir immer mehr Sorgen, ob man dieses "Treiben" als charttechnisches Depot gelten lassen darf ... ;-)) Gruß Chinaman |
| prof - Dienstag, 9. Januar 2007 - 17:39 |
| Und schon haben wir den ersten Fehler in 2007: SL nicht eingehalten, die Quittung kommt prompt ... Prof |
| chinaman - Mittwoch, 10. Januar 2007 - 03:40 |
| "Und schon haben wir den ersten Fehler in 2007: SL nicht eingehalten, die Quittung kommt prompt ... " Hallo Prof, scheint ja ein "Serienfehler" zu sein, denn auch bei K+S scheinst Du Deiner "konsequenten" S/L-Strategie untreu geworden zu sein ... Bezüglich Coeur: Verkaufen tust Du aber trotzdem nicht, oder ??? Gruß Chinaman |
| prof - Dienstag, 23. Januar 2007 - 16:59 |
| Verkauf alle zum nächsten Frankfurter Kurs! Während Silber recht gut läuft, kommt meine Mine nicht aus den Puschen. Im Gegensatz zu Silber kann eine Mine schon "pleite" gehen oder zumindest schlecht performen! Prof |
| chinaman - Mittwoch, 24. Januar 2007 - 10:53 |
| dann kann Coeur ja nun steigen ... ;-)) Gruß Chinaman |
| pumi - Freitag, 9. Februar 2007 - 21:49 |
| @Chinaman wie beurteilst Du zur Zeit die Lage in Bolivien, insb. hinsichtlich der Verstaatlichung von Rohstoffen? Angesichts der wieder anziehenden Edelmetallpreise denke ich über einen Einstieg nach. Sollten die anvisierten 8 Mio. Unzen Silber ab 2008 aus der Mine in Bolivien realistisch sein. Die politische Instabilität bereitet mir jedoch ein wenig Sorgen, vor allem weil mir jegliches Wissen fehlt, um die Lage auch nur annähernd zu beurteilen. Was ich im Internet gefunden habe (auswärtiges Amt, cia.gov, Wikipedia), ermuntert nicht gerade. Grüße, Pumi |
| chinaman - Samstag, 10. Februar 2007 - 09:12 |
| @ Pumi: Ich wäre bezüglich Engagements in Bolivien auch einerseits eher vorsichtig, die Gemengelage ist gefährlich ... Andererseits ist die Situation natürlich bekannt und "eingepreist" Coeur stehe ich daher momentan eher neutral gegenüber ... Gruß Chinaman |
| pumi - Freitag, 11. Juli 2008 - 19:53 |
| Nachdem die Aktie im letzten Halbjahr nur eine Richtung kannte, hab ich auf dem aktuellen Niveau nun auch hier eine kleine Position ins Depot aufgenommen. Der Silberpreis ist ja seit Monaten stabil auf einem relativ hohen Niveau. Coeur wird im nächsten Jahr deutlich weniger Investitionen tätigen und so hoffentlich ordentlich Geld verdienen. Ich kenn mich zwar gar nicht auf dem Gebiet aus, aber jetzt hab ich auf jeden Fall mal eine ganz andere "Sorte" von Aktie im Depot. :) Ein schönes Wochenende wünscht Pumi |
| prof - Freitag, 11. Juli 2008 - 20:11 |
| Silber - Aktien Die performen zur Zeit deutlich schlechter als das Metall, könnte an den gestiegenen Kosten liegen! Coeur Waren früher eine "Markenaktie". Aber der Chart kennt nur eine Richtung. Ich vermute mal politische Risiken in Bolivien oder so. Sieh dir die Mine mal bei http://www.goldseiten.de an. Die haben eine schöne Minenecke! Für mich kommen aktuell nur SSRI und Silver Wheaton in Frage, die sind einigermaßen stabil. Allerdings könnte es schon sein, dass bei einer Silberpreisexplosion Coeur besonders stark steigen. Prof |
| lambo111111 - Sonntag, 21. September 2008 - 16:00 |
| $$ CLXN - Strong Buy - Huge News - Great News and Great 8-K $$ CLX Medical, Inc. Files Form 8-K on Definitive Agreement for the Acquisition of the ThyroTest(R) Rapid Screening Device 2008-09-17 10:02 ET - News Release MURRIETA, CA -- (MARKET WIRE) -- 09/17/08 CLX Medical, Inc. (OTCBB: CLXN), which is focused on the marketing and distribution of unique medical diagnostic testing products, has filed a Current Report on Form 8-K regarding its planned purchase of ThyroTest®, a rapid thyroid stimulating hormone (TSH) screening device used for the detection of hypothyroidism in adults, a common thyroid disease. The Form 8-K can be accessed through a link to SEC filings in the "Corporate" section of the CLX Medical website, www.clxmedical.com. The Form 8-K reports that on September 9, 2008, CLX Medical entered into a product purchase agreement with ThyroTec, LLC, the developer of the ThyroTest® device, pursuant to which CLX Medical will acquire from ThryoTec the exclusive, worldwide rights to ThyroTest®, together with related packaging and marketing materials. The purchase price for the acquisition consists of a cash payment of $750,000 upon closing and the issuance of Series C convertible preferred stock of CLX Medical convertible into fifteen percent (15%) of the total, fully-diluted common stock of the company. Upon closing, Jim Small, ThyroTec's chief executive officer, or his designate will be appointed as a member of CLX Medical's board of directors. Mr. Small has 30 years of thyroid related pharmaceutical experience and is the co-founder of ThyroTec. A detailed biography of Mr. Small will CLXN - CLX Medical entered into a product purchase agreement with ThyroTec, LLC, the developer of the ThyroTest® device, pursuant to which CLX Medical will acquire from ThryoTec the exclusive, worldwide rights to ThyroTest®, CLX MEDICAL INC Local-Id: 125649301 ISIN: US1256493016 Symbol: CLXN Habdelbar in USA: an der OTCBB CLX MEDICAL, INC. OTC BB: CLXN) CLX MEDICAL, INC. www.clxinvestments.com) holds a 51% equity interest in Zonda, Inc. CLX has also invested, and holds a common stock position, in ActionView International, Inc. CLXN Main Corporate Offices... 29970 Technology Drive Suite 203 Murrieta, California 92563 Telephone: (951) 677-6735 Fax: (951) 677-6573 Zonda Corporate Office & Mailing Address Zonda Inc. 17304 Preston Road Suite 800 Dallas, Texas 75248 Ph: 214 438-3706 Fx: 972 733-6817 Zonda lab: 1781 Vineyard Drive #225 Antioch, Ca. 94509 Ph: (925) 755-0511 Fx: (925) 755-0811 Email: General Information: info@zondaincusa.com Sales/Distribution: sales@zondaincusa.com CLXN Directors/Executive Officers Vera Leonard 63 President and chief executive Officer http://www.portfolio.com/resources/executive-profiles/1345872 Robert McCoy 63 DIR James Bickel 69 DIR Patrick Edgerton 62 DIR Transfer Agent Transfer Online 317 SW Alder St., 2nd Floor Portland, OR 97204 Phone (503) 227-2950 Fax (503) 227-6874 CLXN Website http://www.clxinvestments.com/ Authorized Shares: 1,980,000,000 (10-Q/A 12/31/2005) Outstanding Shares: 470,035,668 (Pinksheets 4/8/2008) Estimated Market Cap: 658,050 (Pinksheets 4/24/2008) Shareholders of Record: 582 (Pinksheets 12/31/2007) Zonda Patent Application CLX recently announced plans to initiate clinical trials for Zonda's rapid point of care test for Chlamydia as part of the process to achieve FDA clearance for the product. CLX anticipates a mid to late first calendar quarter 2008 beginning for the clinical trials. Concurrently, CLX will be considering additional medical diagnostic products and technologies that may be acquired and/or licensed by CLX. Investor Relations Gemini Financial Communications Email: investors@clxinvestments.com or abeyer@geminicommunications.com Gemini Financial Communications Andrew Beyer 951-677-8073 SEC Filings http://www.secinfo.com/$/SEC/Registrant.asp?CIK=317438' Other Filings http://www.sarasotaclerk.com/ Stock Manipulation http://www.basherbusters.com/information?information_id=534 Zonda, Inc. CLX also owns a 51% equity interest in Zonda, Inc., a privately held diagnostic testing company that produces diagnostic tests that serve the medical, bacterial food safety, cosmetic, beverage, pharmaceutical, veterinary, and environmental sanitation testing markets. Zonda distributes its HandiLab products in Europe to both the OTC (over the counter) and POC (point of care) markets. The unique features and advantages of HandiLab have resulted in distribution expansion into most countries of Europe. Zonda is undertaking regulatory approval in the U.S. and Asia, as well as expanding the CE certification it has already earned in Europe. Distribution relationships are being negotiated with many additional companies around the world. Zonda’s products for the food safety and environmental sanitation markets are unique to Zonda and are not offered or manufactured by any other company. All of Zonda’s food and environmental safety products provide savings in cost and time to these markets. Zonda’s introduction of QuikAlert was in response to the e-coli and Salmonella outbreaks that have affected the food supply over the past several years. QuikAlert is a useful screening tool that can be used to prevent the spread of bacterial food contamination and assure everyone of a safer food supply. Zonda is expanding into the largest medical sector, the clinical laboratory market, with its introduction of its LabQuik product line. The LabQuik product line of culture confirmation spot tests, stains and reagents are offered at very competitive prices http://www.zondaincusa.com/index.php' QuickAlert Video (e-coli test product): http://www.zondaincusa.com/index2.php?id=video NEW! HandiLab Testing Device Video:http://www.zondaincusa.com/videos/HL-Procedure/HandiLab.html State of Incorporation: Nevada Corporate Address: PO Box 475 Rio Vista, CA 94571 Telephone 925-755-0511 Fax 925-755-0811 Zonda - Management Patrick L. Edgerton - Chairman, Vice President of U.S. and European Distribution Vera Leonard - President/CEO Pavel Holik - Director of Commercial Operations Ms. Leonard has considerable successful experience in leadership positions with major medical manufacturing and distribution companies. From 1999 to 2003 Ms. Leonard served as vice president of U.S. sales for Quidel Corporation, a Nasdaq listed company that specializes in rapid, point-of care diagnostic tests, Ms. Leonard led negotiations on agreements that added approximately $8 million in annual revenue and helped to grow revenues from $32 million to $51 million in 3 years. She delivered an unprecedented 6 consecutive quarters of financial performance that met or exceeded expectations and saved more than $1,500,000 annually for the company from renegotiations of growth incentive plan, implementation of net pricing strategy and elimination of GPO administration fees. Under Ms. Leonard's leadership, the company received awards for outstanding sales performance and distribution partnering from industry-leading distributors 3 years in a row and 4 years total. She restructured the sales and support organization to establish standards of performance, goal-driven compensation plan, territory-level budget and forecast management while developing individuals for promotion to levels of greater responsibility and leadership. From 2004 to 2005 Ms. Leonard served as director of vendor relations for Henry Schein, Inc., a Fortune 500 distributor of medical and dental supplies to office-based practices worldwide. In this position, she launched 6 new products; negotiated semi-exclusive distribution rights on three innovative new products; designed a product launch template that was adopted for standard use by the entire medical marketing team; negotiated an exclusive special pricing agreement on market-leading product to maximize competitive conversions; and completed an in-depth pricing analysis by vendor, sales division and SKU to assess pricing strategies and assure competitive positioning while maximizing profitability. From 2005 to 2007 Ms. Leonard served as President of Vera Leonard, Inc., an alliance that provides business consulting, leadership development, sales training and executive coaching to individuals and corporations. Previous to these positions, Ms. Leonard served as sales representative, sales manager, regional sales manager, and national sales manager for medical manufacturing and distribution companies where she developed an extensive firsthand knowledge of the medical supply field. These companies ranged from start-ups to major U.S. and international firms. Clinical Sample Storage In preparation for planned clinical trials for Zonda's rapid point of care test for Chlamydia, the tests that will be used in the trials have been placed in an FDA compliant, GMP approved secure storage facility provided by Sentry Logistic Solutions ("Sentry"), a leading provider of temperature-controlled storage and third party logistics. Sentry offers refrigerated, ambient, frozen and ultra low storage, logistics and distribution services for a broad range of clinical and commercial biopharmaceutical materials and components. Its experienced staff and 53,000 square-foot facility can handle virtually any storage need and enhance a client's supply chain capabilities. In anticipation of the initiation of clinical trials scheduled for the mid- to late-1st calendar quarter of 2008, Sentry has received a sufficient supply of Chlamydia tests in bulk and will disseminate them for use in the trials as appropriate. Sentry will also provide additional services related to the storage and distribution of the tests including cold chain logistics, labeling and packaging. For additional details regarding Sentry's capabilities and services, please visit http://www.sentrylogistic.com/services.php. Vaildation Studies IIT Research Institute (IITRI) (http://www.iitri.org) will serve as the laboratory that will conduct a validation study for Zonda's rapid point of care test for chlamydia. A major purpose of the validation study is to perfect the testing protocol in preparation for the clinical trials as part of the process to achieve FDA clearance for the product. IIT Research Institute has provided non-clinical research and development services to the U.S. government and to sponsors in the pharmaceutical, biotechnology, chemical, agrichemical, and personal products industries for more than 40 years. IITRI scientists work closely with its sponsors to plan and implement programs in drug discovery, efficacy evaluation, and non-clinical development. Data from GLP-compliant programs conducted at IITRI are commonly used to support Investigational New Drug applications (INDs), New Drug Applications (NDAs), and other submissions to regulatory agencies around the world. IITRI operates more than 125,000 square feet of state-of-the-art laboratory and support space in its Chicago facility. Clinical Trials American Health Partners, LLC (AHP), under which AHP will assist with the launch of medical diagnostic testing in CLX subsidiary operations. The first product for which CLX is expected to utilize AHP's market readiness process and distribution management system is Zonda's rapid point of care test for Chlamydia. The professional services agreement outlines the services that AHP is expected to provide, including preliminary market validation for product efficacy, establishment of clinical trials protocol to meet the appropriate regulatory requirements, completion of clinical trials, assistance with targeted regulatory approvals for distribution of products within the United States, a market readiness audit, a manufacturing plan, a marketing plan, and a distribution plan to include the identification of and a contract with "1st Choice" distributors. AHP (http://www.ahpartners.com) has over 30 years of experience in the marketing and distribution of professional medical products and has experience in preparing products for market launch in the United States. Safis Solutions (http://www.safis-solutions.com), an Indianapolis-based regulatory compliance consulting company serving pharmaceutical, medical device and biotech companies worldwide, has been retained as a sub-contractor of American Health Partners, LLC (AHP), which has been engaged by CLX to assist with the launch of medical diagnostic testing products in its subsidiary operations. Safis Solutions is providing ongoing consulting services in the areas of regulatory approvals and quality systems for Zonda and additional potential future medical diagnostic technologies acquired by CLX. Contract Research Organization (CRO) for the clinical trials for Zonda's rapid point of care test for chlamydia. Trial Care International, LLC (http://trialcareintl.com/index.html) specializes in the management of Phase I-IV clinical trials in a wide range of therapeutic areas and provides clinical management, monitoring, auditing and regulatory services to the pharmaceutical and biotech industry through partnering and long-term relationships with its clients. TCI offers a full range of clinical services specializing in: protocol design, project management, investigator recruitment and selection, document collection and supply shipping, contract and grant administration, investigator meeting coordination and facilitation, monitoring, GCP auditing and regulatory consultin 4/30/08 LOI for FDA approved CLIA waived test kit CLXN announced that after a period of initial due diligence and negotiations, the company has progressed to a letter of intent to acquire a rapid diagnostic device for the medical market. The due diligence process will continue as CLX pursues a definitive agreement and the close of the acquisition of the device. Once CLX has reached a mutually agreed upon point in its due diligence process, it will announce the name of the device and the market that it serves. The acquisition target presents considerable synergies with the product line of Zonda, Incorporated, a majority owned subsidiary of CLX that has developed a rapid point of care test for chlamydia. CLX is currently preparing to initiate clinical trials for the Zonda chlamydia test as part of the effort to achieve FDA clearance for the product. The company recently announced a validation study to perfect the testing protocol in preparation for the clinical trials. :) 2008 UPDATED PRODUCT LAUNCHES!!!! :) Chlamydia: - Clinical trials underway for FDA clearance. Targeted to Launch at the end of Q2 2008 Gonorrhea: - Targeted to Launch Q3 2008 Strep-A: - Targeted to Launch Q3 2008 Yeast: - Targeted to Launch Q3 2008 Get the latest NEWS Releases: http://finance.yahoo.com/q?s=CLXN.OB Get the Latest SEC info: http://finance.yahoo.com/q/sec?s=CLXN.OB Get the Latest Company Events: http://finance.yahoo.com/q/ce?s=CLXN.OB FACTS ABOUT HandiLab *Rapid *Self-Contained *Point of Care and OTC (self testing) ...... Dianostic System Core technology Proprietary enzyme detection system (patent pending) consisting of a synthetic substrate which, in the presence of an enzyme specific to the infectious disease, causes a chemical reaction. This reaction, when coupled to a developing agent, causes a color to appear on the tip of the swab. Competing Technologies to HandiLab *Culture *Nucleic Acid Probe *Antigen Detection *Polymerase Chain Reaction (PCR) Advantages of HandiLab *NOequipment needed *NOexpensive instrumentation necessary *NOadditional reagents to store *NOoff-line extraction; self-contained *NOexpensive employee training *3easy steps *FASTresults at point-of-care *DIAGNOSEand treat patients in same visit Customers for HandiLab Point of Care - Doctors Offices Laboratories Public health/STD Clinics University Health Clinics Over The Counter (OTC) Pharmacies What does CLIA waived mean? http://www.fda.gov/cdrh/clia/cliawaived.html A list of CLIA waived tests since 2000: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfClia/testswaived.cfm http://www.zondaincusa.com/documents/Hungarian%20PCR-HandiLab2.pdf http://www.zondaincusa.com/documents/Poster_Session.pdf http://www.unicorp.hu/docs/b_handylab_uk.pdf http://investorshub.advfn.com/boards/read_msg.asp?message_id=29188980 Posted by: ThePennyGuru For the newbies- Here is what is going on with CLXN: 1. An LOI for a FDA approved CLIA waived Rapid test kit is expected anytime. CLIA waived means it can be done in a Doctor's office and does not have to be sent to a lab. They will have a product that can produce alot of revenues immediately. 2. Validation Studies are underway. Basically, a culture of Clamidia is grown in the lab. They then test to see if the chemical agent of the test kit reacts to the culture. Proof the science works. This is more a formality as the test works. Once this is done the product can be sold in Europe, S. America and most of Asia as they do not require FDA approval. Once the culture is grown, the testing takes 2-3 days. The validation studies are used to train the lab people on the protocols that will be used in the clinical trials. This will be completed by the end of May. 3. Announcement of the European Distributor- I believe this company will handle the rest of the world also. 4. Once Validation studies are done, they will move on to the clinicals. This is a test kit so the clinicals are very simplistic. They need to test a certain number of patients to see if it works 400-600. The clinicals will take less than 2 weeks. I am looking for FDA approval by end of Summer to early fall. Then they will have the product China FDA approved. 5. Once the Clamidia test kit has FDA approval, they will move on to Gonorrhea. This test kit will be bigger than the Clamidia test kit. |
| al_sting - Sonntag, 21. September 2008 - 17:27 |
| Ach, bitte keinen Pennystock-Spam bei stw-Boerse! |